If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
phosphorylation Aside from cleavage, phosphorylation is perhaps the most important chemical modification of proteins. A phosphate group can be attached to the sidechain hydroxyl group of serine, threonine and tyrosine residues, adding a negative charge at that site and producing an unnatural amino acid. Such reactions are catalyzed by kinases and the reverse reaction is catalyzed by phosphatases. The phosphorylated tyrosines are often used as "handles" by which proteins can bind to one another, whereas phosphorylation of Ser/Thr often induces conformational changes, presumably because of the introduced negative charge. The effects of phosphorylating Ser/Thr can sometimes be simulated by mutating the Ser/Thr residue to glutamate. glycosylation A catch-all name for a set of very common and very heterogeneous chemical modifications. Sugar moieties can be attached to the sidechain hydroxyl groups of Ser/Thr or to the sidechain amide groups of Asn. Such attachments can serve many functions, ranging from increasing solubility to complex recognition. All glycosylation can be blocked with certain inhibitors, such as tunicamycin. deamidation (succinimide formation) In this modification, an asparagine or aspartate side chain attacks the following peptide bond, forming a symmetrical succinimide intermediate. Hydrolysis of the intermediate produces either aspartate or the β-amino acid, iso(Asp). For asparagine, either product results in the loss of the amide group, hence "deamidation".
A highly abundant weed species in Papaver somniferum fields was shown to be Papaver rhoeas. Papaver somniferum and Papaver rhoeas are congeners and belong to the same plant family, which impedes the chemical control of this weed species. Therefore, weed management represents a big challenge and requires technological knowledge from the farmer. In order to increase the efficiency of weed control not only chemical weed control should be applied but also mechanical weed control. For P. somniferum, a growth density of 70 to 80 plants per square metre is recommended. Latex-to-biomass yield is greatest under conditions of slight water deficit.
=== Legal status === Bulevirtide was approved for medical use in the European Union in July 2020, in Canada in August 2025, and in the United States in May 2026. The US Food and Drug Administration granted the application for bulevirtide priority review, breakthrough therapy, and orphan drug designations.
Sources: en.wikipedia.org
=== Post-translational modifications and cofactors === Phosphorylation of the N-terminus not only prevents MDM2 binding but also facilitates the recruitment of cofactors. Pin1 enhances conformational changes in p53, while p300 and PCAF acetylate the C-terminus, exposing the DNA-binding domain and enhancing transcriptional activation. Conversely, deacetylases such as Sirt1 and Sirt7 remove these modifications, suppressing apoptosis and promoting cell survival. Some oncogenes can also activate p53 indirectly by inhibiting MDM2.
=== Mining and oil, and gas industry === Antiscalants are used in mining operations and oil & gas production to prevent scale deposition in pipelines, drilling equipment, and processing facilities. Scaling in these industries can lead to decreased flow rates, equipment damage, and production downtime. Preventing the formation of scale from blocking or hindering fluid flow through pipelines, valves, and pumps used in oil production and processing. Oilfield scaling is the precipitation and accumulation of insoluble crystals (salts) from a mixture of incompatible aqueous phases in oil processing systems.
Ukraine claimed that two S-300 missiles hit a hospital in Kharkiv, injuring one man. The Ukrainian Air Force claimed to have intercepted 21 out of 34 Russian missiles. Attacks severely damaged equipment at four thermal power plants in Dnipropetrovsk, Ivano-Frankivsk, and Lviv Oblasts causing blackouts. Two people were injured in Kryvyi Rih. During a visit to Lviv, Australian Defence Minister Richard Marles announced a $100 million AUD military aid package for Ukraine that included drones, short range air defences, air dropped precision munitions and other "high-priority equipment". Two Ukrainian soldiers were killed in a stabbing attack by a Russian national in Murnau am See, Germany, in what authorities said may have been a politically motivated attack.
Sources: en.wikipedia.org
Phosphate – used for the production of nucleic acids, phospholipids (an important component of the cell membrane) and ATP (Adenosine triphosphate which the cell uses for transferring energy for metabolism). Potassium – important for the uptake and utilization of phosphate Biotin – involved in the synthesis of proteins, fatty acids and nucleic acids. Pantothenic acid – involved in the metabolism of sugars and lipids. A deficiency of this vitamin could lead into increase hydrogen sulfide production with off-aromas in the resulting wine. Nicotinic acid – involved in the synthesis of Nicotinamide adenine dinucleotide (NAD+), a co-enzyme that is important in maintaining the redox balance of the cell as well as in the process of ethanol fermentation itself. Inositol – involved with the secondary messenger molecules that facilitate cell division. Trace amounts of calcium, chlorine, copper, iron, manganese and zinc for healthy cell function.
== Composition == Diatomaceous earth consists of the fossilized remains of diatoms that accumulated over millions of years. It is usually composed of 80% to 90% silica, 2% to 4% alumina minerals, and 0.5% to 2% iron oxide, although the precise composition of every deposit is different. Deposits may contain different amounts of silica depending on the sedimentation conditions, the presence of other sediments (clay, sand, volcanic ashes), and the age of the deposit (diagenesis, silica (SiO2) dissolution/precipitation, diatoms tests ageing). The species of diatom may also differ among deposits. The species of diatom is dependent upon the age and paleoecology of the deposit. In turn, the shape of a diatom is determined by its species. Many deposits throughout British Columbia, such as Red Lake Earth, are from the Miocene epoch and contain a species of diatom known as Melosira granulata. These diatoms have a small globular shape. A deposit containing diatoms from this epoch can provide certain benefits over others. For example, diatoms from the Eocene epoch are not as effective in their ability to absorb fluids because as older diatoms recrystallize, their small pores become filled with silica.
On May 20, 2014, Riff Raff announced through his Twitter that after much delay, Neon Icon was scheduled for a June 24, 2014, release date. The same day the official track listing for the album was revealed, which included previously announced collaborations Mac Miller, Childish Gambino, Paul Wall, Mike Posner and Amber Coffman of Dirty Projectors as well as Slim Thug. On the 2015 Vans Warped Tour, Riff Raff hired We Came As Romans' bassist Andy Glass to play bass for him on the tour.
Selenium deficiency occurs when an organism lacks the required levels of selenium, a critical nutrient in many species. Deficiency, although relatively rare in healthy well-nourished individuals, can have significant negative results, affecting the health of the heart and the nervous system; contributing to depression, anxiety, and dementia; and interfering with reproduction and gestation.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.